TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“ Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed two additional international patent applications that bring the potential to obtain patent coverage in 153 countries for each of the patent applications. The application, governed by the Patent…


Previous articleWesana Health Highlights Recent Appointments to Board of Directors
Next articleExploring the Role of Serotonin 2A Activation in LSD’s Effects on Empathy